Jigar Raythatha - 13 Sep 2021 Form 4 Insider Report for Jounce Therapeutics, Inc.

Role
Director
Signature
/s/ Elizabeth Shortsleeve, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
13 Sep 2021
Net transactions value
$0
Form type
4
Filing time
15 Sep 2021, 08:16:22 UTC
Previous filing
19 Jul 2021
Next filing
28 Jun 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction JNCE Common Stock Award $0 +31,400 $0.000000 31,400 13 Sep 2021 Common Stock 31,400 $6.47 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on September 13, 2021 and will vest in equal quarterly installments during the twelve quarters following the grant date, subject the to Reporting Person's continued service as a director.